EPLUS Research Company - a comprehensive strategic partner of VNVC Immunisation System and GSK Vietnam Pharmaceutical Co., Ltd., a member of the world's leading pharmaceutical group GSK signed a memorandum of strategic cooperation, on July 3.
This event opens an opportunity for EPLUS's strategic partner, the VNVC Immunisation System, to bring to Vietnam many new and scarce vaccines with a large number of vaccinations for people, towards the goal of increasing overall vaccination coverage, especially for high-risk groups such as pregnant women, the elderly, and people who have underlying medical conditions.
EPLUS is a pioneer company in the field of providing ancillary services for the health industry, including the import, distribution and supply of vaccines. Currently, EPLUS has imported and supplied vaccines from many of the world's leading vaccine manufacturers to the VNVC Immunisation System.
This cooperation is expected to quickly bring new, high-quality essential vaccines, manufactured from large factories located in Belgium or Italy to more Vietnamese people.
Ngo Chi Dung, Chairman of the Board of Directors of EPLUS Research Joint Stock Company, said that the company has invested in the leading modern vaccine supply network in Vietnam with nearly 120 cold storage units meeting Good Storage Practices (GSP) standards and a cold chain system at each VNVC vaccination centre, specifically the system of three deep negative cold storages, which preserves vaccines at minus 86 degrees Celsius.
At the signing ceremony, Luis Arosemena, Senior Vice President, GSK Emerging Markets Region, emphasised that Vietnam is one of GSK's five priority markets out of more than 100 countries in the region.
